Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | BLM | P54132 | 1/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL146048 | 0.85 | KDM4E (0.56) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL16474401 | 0.83 | HSD17B10 (0.43) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL16474399 | 0.83 | KMT2A (0.50) | ALDH1A1HSD17B10KDM4EMAPTSMN1; SMN2 | |
| SCHEMBL10059414 | 0.82 | MAPT (0.61) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL11896477 | 0.82 | KDM4E (0.53) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL11316543 | 0.82 | BLM (0.53) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL13075771 | 0.81 | ALDH1A1 (0.57) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL142307 | 0.81 | KDM4E (0.53) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL16474400 | 0.81 | ALDH1A1 (0.52) | HPGDALDH1A1HSD17B10KDM4ECYP1A2 | |
| SCHEMBL16474398 | 0.81 | KMT2A (0.47) | ALDH1A1MAPTLMNAGAAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-19 | — | — | US | disclosed |
| CN-110028442-B | Simple preparation method of Perampanel | 新发药业有限公司 | 2020-07-17 | — | — | CN | disclosed |
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | XELLIA PHARMACEUTICALS APS (DK) | 2020-07-14 | — | — | US | disclosed |
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | XELLIA PHARMACEUTICALS APS (DK) | 2020-05-05 | — | — | US | disclosed |
| US-10544161-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2020-01-28 | — | — | US | disclosed |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | GENENTECH, INC. | 2019-10-24 | — | — | US | disclosed |
| US-10376497-B2 | Anti-fibrotic pyridinones | INTERMUNE, INC. (US) | 2019-08-13 | — | — | US | disclosed |
| EP-3166960-B1 | LOW SUBSTITUTED POLYMYXINS AND COMPOSITIONS THEREOF | XELLIA PHARMACEUTICALS APS (DK) | 2019-08-07 | — | — | EP | disclosed |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | GENENTECH, INC. | 2019-05-16 | — | — | US | disclosed |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009149188-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | INTERMUNE, INC. (US) | 2009-12-10 | — | — | WO | disclosed |
| EP-1948178-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | Intermune, Inc. (US) | 2008-07-30 | — | — | EP | disclosed |
| EP-1928454-A2 | PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | Intermune, Inc. (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007062167-A9 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE INC (US) | 2007-07-26 | — | — | WO | disclosed |
| WO-2007062167-A2 | METHOD OF MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007053685-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | INTERMUNE, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007053685-A2 | METHODS OF TREATING ATRIAL FIBRILLATION WITH P38 INHIBITOR COMPOUNDS | INTERMUNE, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | INTERMUNE, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006122154-A2 | PYRIDONE DERIVATIVES FOR MODULATING STRESS-ACTIVATED PROTEIN KINASE SYSTEM | INTERMUNE, INC. (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10544161-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | HPGD 298/4885ALDH1A1 529/4885HSD17B10 2171/4885 |
| US-20190321343-A1 | Anti-Fibrotic Pyridinones | MMP1, COL1A1, COL2A1 | HPGD 298/4885ALDH1A1 529/4885HSD17B10 2171/4885 |
| US-10640536-B2 | Polymyxins, compositions, methods of making and methods of use | C5, HRH3, SGMS1 | HPGD 3594/4885ALDH1A1 4877/4885HSD17B10 2236/4885 |
| US-10376497-B2 | Anti-fibrotic pyridinones | MMP1, COL1A1, COL2A1 | HPGD 298/4885ALDH1A1 529/4885HSD17B10 2171/4885 |
| US-20090318455-A1 | COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS | MAP3K8, MAP3K1, MAP3K6 | HPGD 529/4885ALDH1A1 2054/4885HSD17B10 2915/4885 |
| US-20200361994-A1 | PEPTIDE ANTIBIOTICS | NGLY1, VIP, PEPD | HPGD 3755/4885ALDH1A1 4862/4885HSD17B10 4233/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | HPGD 3755/4885ALDH1A1 4862/4885HSD17B10 4233/4885 |
| US-20060270612-A1 | Method of modulating stress-activated protein kinase system | MAPKAPK2, MAP3K6, MAP4K1 | HPGD 995/4885ALDH1A1 3375/4885HSD17B10 3533/4885 |
| US-20190144467-A1 | ANTI-FIBROTIC PYRIDINONES | MMP1, COL1A1, COL2A1 | HPGD 298/4885ALDH1A1 529/4885HSD17B10 2171/4885 |
| US-10711040-B2 | Low substituted polymyxins and compositions thereof | TLR3, TLR4, TLR5 | HPGD 3674/4885ALDH1A1 4882/4885HSD17B10 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.